Caligan Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Caligan Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,200,000	Closed	-$22.2M	–	13
2023 Q3	$22.2M	Hold	1,200,000	–	–	10.22%	3
2023 Q2	$13.3M	Buy	+1,200,000	New	+$16.7M	7.46%	6

Caligan Partners's ICPT Position: Q3 2023 in Review

Caligan Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 1,293,510 shares — an estimated $14.6M sold.

Caligan Partners first reported a position in ICPT in Q2 2023 and held it in 1 quarter. The position peaked at $14.3M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

Caligan Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Caligan Partners sold 1,293,510 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $14.6M.
Caligan Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
Caligan Partners's Intercept Pharmaceuticals, Inc. position peaked at $14.3M in Q2 2023.
146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Caligan Partners's 13F filing for Q3 2023, filed 14 Nov 2023.